(TCON) 0.32 - MC $9 m - pivotal interim data imminent (sarcoma drug) ...super cheap cancer play who could file NDA by mid next year a potential 10 bagger and more here guys
“We look forward to reporting the interim efficacy assessment from ENVASARC in the third quarter of 2023, which includes a futility analysis that we have already met based on responses seen to date.”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.